Sainte-Monique: landslide or sinkhole?
After a home in Saint-Monique, Que. was consumed by a massive hole, Dr. Kirsten Rempel explains the difference between a landslide and a sinkhole.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
21 minutes ago
- National Post
NatureCounts App Launches, Introduces Point Count Technology to Support Bird Conservation
Article content Birds Canada and Punchcard Systems revolutionize how bird populations are tracked and protected with the unveiling of novel point count technology. Article content Article content EDMONTON, Alberta — In response to the stark decline of bird populations in North America, Birds Canada, working together with Punchcard Systems, has officially launched the NatureCounts mobile app, an intuitive digital tool that empowers conservationists, scientists, and volunteers to collect data faster, more accurately, and at greater scale than ever before. Article content Collapsing bird numbers show no signs of stopping. Since 1970, North America has lost nearly 3 billion birds. In Canada alone, well over a third of bird species have declined over the same period, according to the 2024 State of Canada's Birds Report. Birds play a critical role in healthy ecosystems, and their populations signal broader environmental changes, making their decline a warning sign for biodiversity at large and creating an immediate need for better tools to understand which species are at risk, why they are declining, and how to act swiftly. Article content 'With bird populations in crisis, we need better data and faster action,' said Catherine Jardine, Associate Director of Data Science and Technology at Birds Canada. 'NatureCounts makes that possible by empowering Citizen Scientists, researchers, and volunteers to collect high-quality information and drive urgent, informed decisions to protect our birds and our ecosystems.' Article content At the core of the new NatureCounts app is the point count interface, a one-of-a-kind tool that digitizes one of the most critical and widely used bird monitoring methods in conservation science. By integrating satellite imagery, precise GPS mapping, and a mobile-first design, the new point count tool replaces a traditionally paper-based, time-intensive process with an intuitive, efficient, and scalable solution. Early trials show the technology has already saved over five years' worth of manual data entry, freeing up valuable time for analysis and action. Article content 'At Punchcard, we're proud to partner with organizations tackling urgent, real-world challenges, and Birds Canada is a perfect example,' said Sam Jenkins, Managing Partner at Punchcard Systems. 'This collaboration brought together deep field expertise and thoughtful technology design to strengthen, not replace, traditional conservation methods. NatureCounts represents a powerful step forward in global conservation, and we're proud to support Birds Canada in leading that charge.' Article content Key features of the NatureCounts app include: Article content Mobile-first data collection: Designed for smartphones and tablets, the NatureCounts app enables users to capture detailed observations in the field, even offline. GPS and satellite-enabled interface: Interactive mapping ensures accurate geolocation and route planning for repeatable surveys. Flexible protocol customization: Supports more than 80 biodiversity monitoring programs, including regional, national, and international standards. Offline functionality: Built for use in remote and rugged environments with no cell signal. Article content Tens of thousands of individuals in North America are already contributing data through Birds Canada programs. Early adopters of NatureCounts in the United States, including the Pennsylvania Bird Atlas, are reporting transformative improvements in data quality and efficiency. As adoption grows, NatureCounts is poised to support international conservation efforts, including national biodiversity strategies, environmental policy, and species assessments. Article content 'When we started planning the Pennsylvania Bird Atlas point counts, it quickly became apparent that all other existing tools lacked crucial features,' said Amber Wiewel, Coordinator of the Pennsylvania Bird Atlas. 'The NatureCounts mobile app has been the perfect solution for our needs, and I am so impressed with the new point count feature. It's intuitive, efficient, and exactly what we needed to properly collect and manage this critical data.' Article content Birds Canada and Punchcard Systems continue to enhance the platform with new features and improvements planned for 2025 and beyond. Article content About Birds Canada Birds Canada is a national charitable organization whose mission is to drive action to increase the understanding, appreciation, and conservation of birds in Canada. Through its many citizen science programs, research projects, and conservation initiatives, Birds Canada generates and uses an enormous amount of conservation data to help protect birds. Article content About Punchcard Punchcard Systems is a Canadian digital transformation innovation consultancy that helps organizations turn complex problems into purposeful, human-centred software solutions. Founded in 2016 by Sam Jenkins and Estyn Edwards, Punchcard was built on the belief that software should be a catalyst for growth, not a hurdle. Recognized as one of Canada's Top Growing Companies by The Globe and Mail, Punchcard partners with over 250 clients across Canada and the U.S., and continues to push the boundaries of what thoughtful technology can do for business, community, and society. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
CTV News
31 minutes ago
- CTV News
Quebec's average ER wait time is now more than 5 hours – longest in the country
Quebecers waited an average of five hours and 23 minutes to be seen in the province's emergency rooms last year, finds a new report by the Montreal Economic Institute (MEI). 'These long wait times are not just numbers — they represent real Canadians who face delays in receiving critical care that cause needless pain or distress,' said Emmanuelle B. Faubert, an economist at the MEI and author of the report. 'In all the provinces, wait times are worse today than they were five years ago, a clear sign that our health care systems are struggling to provide their patients with timely access to care.' According to the report, an average patient visiting a Quebec emergency room in 2024 spent 10 minutes longer waiting than they would have the previous year. This also represents a one-hour increase over the past five years. 'With patients in Quebec having some of the longest emergency room visits in the country, it's clear that things need to change,' said Faubert. 'It's important to note that, while this is the province's median, patients in some parts of the province are unfortunately having to wait even longer for emergency medical care.' The longest emergency room stays in Quebec were in Laval (eight hours), the Laurentians (seven hours and seven minutes) and the Montérégie (six hours and 55 minutes). The Pavillon Albert-Prévost mental health emergency room in Montreal topped the list of longest lengths of stay at 13 hours and five minutes. The second longest was the Royal Victoria Hospital (10 hours and 33 minutes) at the McGill University Health Centre (MUCH) in Montreal and Anna-Laberge Hospital (10 hours and 26 minutes) in Châteauguay on the South Shore.c 'Having to spend long hours waiting in an emergency room may be the norm in Quebec, but in other developed countries, it isn't,' noted Faubert. 'It's clear that solving the issue of long wait times requires looking at best practices from abroad, such as Europe's mixed systems, to finally give patients the timely access they deserve.' In comparison to Quebec's five-hour and 23-minute wait times, the report found that average ER stays across the country last year were as follows:
National Post
41 minutes ago
- National Post
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
Article content Article content – Newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine ('DMT') and deuterated isotopologues for intramuscular injection, including CYB004, with expected exclusivity until 2040 – Article content – Cybin's growing intellectual property portfolio comprises more than 90 granted patents and over 230 pending applications – Article content TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder ('GAD'). Article content The patent, which is expected to provide exclusivity until 2040, includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ('IM') injection, including CYB004. Article content 'Patents are extremely valuable assets, and protection for our lead product candidates is a top priority for us,' said Doug Drysdale, Chief Executive Officer of Cybin. 'We believe that our CYB004 program has the potential to deliver short-duration, rapid-acting treatment for anxiety disorders and offer more patient-friendly dosing methods such as IM administration. The issuance of this additional patent in support of CYB004 adds further validation of this important program. Dosing is currently underway in our Phase 2 study evaluating CYB004 in generalized anxiety disorder, and we expect the study to complete around mid-year. I'm proud that Cybin has amassed one of the strongest IP portfolios in the sector with more than 90 granted patents and over 230 pending applications.' Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's expectations respecting the patent exclusivity period; plans to complete the Phase 2 GAD study around mid-year 2025; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of a pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Contacts Article content Article content Article content
